Company intelligence / Profile preview

DEMI

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Demi is a digital health company focused on metabolic health and medical weight loss through a comprehensive clinical platform. The company provides patients with access to GLP-1 receptor agonist medications, such as semaglutide and tirzepatide, paired with personalized clinical support and health coaching. Demi's business model integrates telehealth consultations with prescription fulfillment and long-term metabolic monitoring to help users achieve sustainable weight loss. By leveraging the latest advancements in obesity medicine, Demi aims to make high-quality metabolic care more accessible and manageable for individuals struggling with chronic weight issues.

Therapeutic areas: Endocrinology
Modalities: Small moleculePeptides
Industry: Non-Academic Healthcare

Beyond the preview

Go deeper on DEMI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DEMI.

Explore the full profile